Dafni deals with various areas of EU competition law, including merger control (M&A and joint ventures), cartel and antitrust investigations, horizontal and vertical agreements and compliance programmes. Dafni advises clients active in a broad range of industries including pharmaceuticals, consumer goods, financial services and energy. Dafni has particular expertise in the pharmaceutical sector, where she advises major international companies on patent settlements and licensing agreements, life-cycle management strategies and merger control issues.
Dafni's experience includes advising:
- a major global bank on the regulatory investigations into foreign exchange rates
- a major global bank on submitting a marker and a leniency application to the European Commission, the UK CMA and a competition authority in a non-EU jurisdiction
- a global innovative pharmaceutical company on various aspects of an abuse of dominance complaint lodged by a generic company to the European Commission and subsequently a national competition authority in the context of IP litigation
- a number of global innovative pharmaceutical companies on patent settlement agreements, the Commission's annual patent settlement monitoring exercise, licensing/technology transfer, vertical agreements and life-cycle management strategies
- AbbVie on the merger control aspects of its proposed £32 billion acquisition of Shire which was unconditionally approved by the European Commission (deal eventually abandoned)
Dafni holds a Master of Laws (LLM) from the University of Cambridge and a Bachelor of Laws from the Aristotle University of Thessaloniki (Hons). Prior to joining HSF, she worked as a trainee in another international law firm in Brussels and completed a traineeship at DG Competition of the European Commission.